Navigation Links
Bionovo, Inc. to Announce First Quarter Fiscal Year 2009 Financial Results on Thursday, May 7, 2009
Date:4/30/2009

EMERYVILLE, Calif., April 30 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today that it will release financial results for the first quarter of fiscal year 2009 ended March 31, 2009 on Thursday, May 7, 2009. The Company will conduct a conference call and webcast to review the financial results on Thursday, May 7, 2009 at 4:30 p.m. ET.

Interested parties can access the call by dialing (877) 356-5706 or (706) 643-0580, or can listen via a live Internet webcast, which can be found at http://bionovo.com/investors/events. A replay of the call will be available via webcast at http://bionovo.com/investors/events for 30 days or by playback at (800) 642-1687 or (706) 645-9291, access code 94818134, through May 10, 2009.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: '/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Bionovo, Inc. to Announce Fourth Quarter and Year-End Financial Results on Thursday, March 12, 2009
2. JAG Media Holdings, Inc. Announces Update of the Status of its Proposed Acquisition of CardioGenics Inc.
3. West Announces First Quarter 2009 Results
4. Nuvo announces 2009 first quarter financial results
5. IRIDEX Announces Shipment of New IQ 577(TM) Laser Systems
6. Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call
7. ThermoGenesis Corp. to Announce Third Quarter Fiscal 2009 Results on May 6, 2009
8. Management Health Solutions, Inc. Announces Release v1.0 to Clinical Inventory Valuation Solution
9. Medeguide Announces Online Marketing Partnership with Admax Plus to Promote Doctors and Treatment Packages Online
10. Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets
11. Stryker Announces Election of New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... new three-drug combination has shown in a phase 1/2 ... regimen" in the treatment of patients newly diagnosed with ... bone marrow, say researchers from Dana-Farber Cancer Institute. , ... the 66 patients treated with the drug combination in ... good partial response rate" in the phase 2 population, ...
(Date:12/5/2009)... Blood Cancer Is Most Challenging-- ,, PHILADELPHIA ... identified specific genes, dubbed partner genes, that fuse with ... in infants. By more accurately defining specific partner genes, ... from particular treatments. ,, Oncologists also aim to ...
(Date:12/5/2009)... Midbrook,s advanced Technology Center helps companies develop and test their cleaning ... in a variety of industries and solve problems for customers relating ... ... (Vocus) December 5, 2009 -- Midbrook, Inc , a Jackson, ...
(Date:12/4/2009)... Systems (NYSE: VAR ) announced today that its ... of Stockholders for February 11, 2010 with a record date ... the Crowne Plaza Cabana Hotel, 4290 El Camino Real, Palo ... be webcast by Thomson Financial and can be accessed at ...
(Date:12/4/2009)... Holdings, Ltd (NYSE: AWH ) today announced ... Sennott, Executive Vice,President and Chief Corporate Strategy Officer, will ... Conference being held at the Goldman,Sachs Conference Center in ... About Allied World Assurance Company ...
Breaking Medicine News(10 mins):Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
... MA--The National Institutes of Health (NIH) has awarded one ... 2008 to a team based at Boston University Medical ... (BMC). These awards, together with 12 CTSAs awarded in ... of an NIH effort to build a national consortium ...
... the focus of the Staying Sharp session on June 3 ... recognized series, the program will emphasize successful aging, including how ... future cognitive function; and the importance of clinical trials and ... member Marwan N. Sabbagh will sign copies of his book, ...
... Pa., May 29 The Pennsylvania,Department of Health today ... 31,observance of "World No Tobacco Day," which is designed ... "Exposure to secondhand smoke causes disease and premature death ... Calvin B.,Johnson. "I encourage all Pennsylvania smokers to set ...
... Ensure Patients Receive High-Value Health Care, WASHINGTON, ... care spending and improve the quality of patient ... Insurance Plans (AHIP) was,implemented. PricewaterhouseCoopers reviewed AHIP,s proposals ... fully implemented, the nation,s,total health care expenditures could ...
... Vanessa Carlton to Help ... Cancer Leader, WASHINGTON, May 29 Breast cancer ... Carlton will join Susan G. Komen for the Cure(R) ... activities leading up to the,19th annual Susan G. Komen ...
... Access by Breaking Through Barriers, NEWPORT NEWS, ... Patient Advocate Foundation today announced a strategic,collaboration that ... families,quick access to timely information and specialized patient ... lives of cancer,patients nationwide who are facing access ...
Other Medicine News:Health News:BUMC, BMC receives Clinical and Translational Science Award from NIH 2Health News:AHIP Outlines Plan to Reduce Health Care Costs by $145 Billion 2Health News:AHIP Outlines Plan to Reduce Health Care Costs by $145 Billion 3Health News:AHIP Outlines Plan to Reduce Health Care Costs by $145 Billion 4Health News:Susan G. Komen for the Cure(R) Celebrity Ambassadors to Convene in Nation's Capital to Help Race for the Cure, End Breast Cancer Forever 2Health News:American Cancer Society, Patient Advocate Foundation Announce Free, Personalized Assistance for Cancer Patients 2Health News:American Cancer Society, Patient Advocate Foundation Announce Free, Personalized Assistance for Cancer Patients 3
(Date:12/4/2009)... Calif., Dec. 4 Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) ... Amended Plan of Reorganization and related amended Disclosure Statement with ... ,, A hearing to consider the adequacy of ... with the hearing on the confirmation of the Plan scheduled ...
(Date:12/4/2009)... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... Principal investigators will discuss the data presentations surrounding carfilzomib ... the 51st American Society of Hematology (ASH) Annual Meeting. ... a.m. ET on Monday, December 7, 2009. The ...
(Date:12/4/2009)... Shared Imaging, LLC, an independent provider of CT, ... hospitals and healthcare providers, is excited to announce ... Ambulatory Health Care, a nationally-recognized, prestigious gold seal ... care. Shared Imaging accreditation is system-wide for its ...
Breaking Medicine Technology:Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2New research program BioInterfaces launched 8742 1New research program BioInterfaces launched 8742 2Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 1Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 2Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 1Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 2Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 3
... CAMBRIDGE, Mass., and BERLIN, Sept. 26 ,Genzyme Corporation ... AG, Germany,today announced that the first patient has ... 3 trials examining the safety and efficacy of ... The CARE-MS I trial (Comparison of Alemtuzumab and ...
... 26 Innocoll, Inc., a privately-held,specialty pharmaceutical company, ... clinical development programs and specialty,pharmaceutical operations: - ... in 2007., - GENTAMICIN ... multi-centered clinical trials for the ...
Other Medicine Technology:Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 2Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 3Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 4Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 5Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 6Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 2Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 3Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 4Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 5Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 6
The Express Plus clinical chemistry analyzer is a fully automated walk away system designed for maximum productivity, convenience and reliability....
Seamlessly integrates with the i2000SR to form a state-of-the-art immunochemistry platform, the ci8200. Flexibility to prioritize STAT, automated rerun/dilution, and reflex testing over routines to e...
... and controls interchangeable with other Roche/Hitachi ... training costs. Consistent patient results throughout ... handling. 70 positions for routine, STAT ... volumes. Intermix sample types. Intermix 5 ...
Modular Pre-Analytics is an integral component of the new modular systems platform which combines pre-analytics, clinical chemistry and immunochemistry....
Medicine Products: